Is bemotrizinol sunscreen FDA approved? What the 2026 monograph order means

FDA did not approve every bemotrizinol sunscreen as a product. A final administrative order effective August 9, 2026 added bemotrizinol, at up to 6%, to the U.S. OTC sunscreen monograph under detailed conditions. A finished sunscreen can use that route only if its active ingredients, concentration, formulation, dosage form, testing, labeling, manufacturing, and any exclusivity limits all comply.¹²

That distinction is the durable story behind the first new U.S. sunscreen active permitted through this pathway in more than two decades. The ingredient now has a lawful monograph route; a bottle does not become “FDA approved” merely because bemotrizinol appears on its label.

A monograph is a rulebook, not a product approval letter

OTC monographs specify conditions under which certain nonprescription drugs can be marketed without an approved new drug application. For sunscreen, the rulebook covers active ingredients, permitted combinations, strength, dosage forms, SPF and broad-spectrum testing, warnings, directions, and other labeling.

The approved-cleared-registered guide explains why those verbs cannot be exchanged. For bemotrizinol sunscreen, “permitted under the monograph when compliant” is more accurate than “FDA-approved ingredient” and much more accurate than “FDA-approved product.”

The order has boundaries

The final order permits bemotrizinol at a maximum concentration of 6% and includes formula, combination, dosage-form, testing, and labeling conditions.¹ It does not authorize any concentration, any mix of filters, any spray or powder, or any claim a marketer chooses.

The order also carries a statutory 18-month exclusivity associated with the sponsor and licensees under the OTC monograph reform process.¹² That can affect who may rely on the order during the exclusivity period. It is not a clinical superiority period, a patent statement, or a promise that a product is already on every shelf.

When a marketplace listing says “same formula Europe has used for years,” verify the U.S. label and seller. A foreign product can have different active ingredients, concentrations, dosage form, warnings, or claims. The FDA order governs the U.S. monograph path, not every international formulation with a similar name.

SPF, broad spectrum, and water resistance are separate claims

SPF primarily measures protection against sunburn-producing ultraviolet radiation under a standardized test. “Broad spectrum” requires its own test and indicates protection across a specified portion of UVA and UVB. Water resistance must be labeled for the tested duration; “waterproof” is not the permitted claim.³

Bemotrizinol’s presence does not erase those separate requirements. A consumer comparison should capture:

• the Drug Facts active ingredients and percentages;
• labeled SPF and broad-spectrum status;
• water-resistance duration, if any;
• dosage form and directions;
• lot, expiration, manufacturer or distributor, and seller; and
• the use context: daily face, outdoor sport, sensitive area, cosmetic layering, or another job.

“UVA filter” does not establish the finished product’s full broad-spectrum performance. The finished formula and standardized testing matter.

Better filtering does not replace usable application

A sunscreen can be technically elegant and still fail the real-world job if someone will not apply enough, misses areas, cannot tolerate the vehicle, or does not reapply in the labeled circumstances. The best formula for a person is one that has an appropriate lawful label and can be used consistently with shade, clothing, hats, and other sun-protection measures.

South Florida conditions make sweat, water exposure, high UV, and cosmetic wear especially relevant. That does not create a separate Florida sunscreen law or justify a city-specific product ranking. It creates practical questions about water resistance, reapplication, eye-area tolerance, and storage in heat.

A five-field product verification

1. Read the U.S. Drug Facts panel. Record every active ingredient, percentage, SPF, broad-spectrum statement, dosage form, directions, and warnings.
2. Match the claim to the record type. Distinguish monograph compliance from a product-specific NDA and reject vague FDA-approved wording.
3. Check the finished product, not only bemotrizinol. Concentration, combinations, vehicle, testing, labeling, and manufacturing all matter.
4. Verify seller and traceability. Preserve manufacturer or distributor, lot, expiration, seller, country label, and purchase record.
5. Choose for the actual use context. Compare water exposure, reapplication, skin tolerance, cosmetics, quantity, and sun-protective behaviors.

The decisive question is not “Is bemotrizinol approved?” It is “Does this exact finished sunscreen have a lawful U.S. pathway and label, and does its tested claim and usable format fit the protection job?”